[A21-25] Esketamine (depression, acute treatment) - Benefit assessment according to §35a Social Code Book V
Last updated 19.08.2021
Project no.:
A21-25
Commission:
Commission awarded on 04.03.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Mental and emotional wellbeing
Adult patients with a moderate to severe episode of major depressive disorder, as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A21-24 | Esketamine (depression) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-91 | Esketamine (depression, acute treatment) - Addendum to Commission A21-25 | Commission completed |
Federal Joint Committee (G-BA)
2021-08-19 A G-BA decision was published.